Obesity & metabolic peptides

GLP-1 & obesity peptides: the complete class guide

This page groups every compound being developed or used for weight loss through the incretin and amylin hormone systems, whether it is a true GLP-1 receptor agonist, a dual or triple agonist, or an amylin analog with no GLP-1 activity at all. Some are FDA-approved; most are still in clinical trials. Each entry links to its own full write-up with dosage data, evidence tiers, and sources.

Browse the peptide index How we grade evidence
4 approved 26 compounds tracked Evidence-tiered
Why amylin analogs are grouped here too: Cagrilintide, petrelintide, and eloralintide do not touch the GLP-1 receptor at all — they work on the amylin receptor instead. They are included because they compete for the same clinical purpose (chronic weight management) and are frequently paired with or compared against true GLP-1 drugs in trials and in the research community. “GLP-1 class” is used loosely here the way it is used in practice: shorthand for the whole incretin-and-amylin obesity drug category, not a strict chemistry label.

Approved

Cleared by the FDA and in general clinical use.

CompoundMechanismStatusDeveloper / brand
SemaglutideGLP-1 receptor agonistApprovedNovo Nordisk (Ozempic, Wegovy)
TirzepatideGIP/GLP-1 dual agonistApprovedEli Lilly (Mounjaro, Zepbound)
LiraglutideGLP-1 receptor agonistApprovedNovo Nordisk (Victoza, Saxenda)
PramlintideAmylin analogApprovedApproved for diabetes (Symlin); amylin-class origin point

Late-stage investigational

In Phase 2 or Phase 3 trials, or approved in one market and still investigational elsewhere.

CompoundMechanismStatusDeveloper
RetatrutideGIP/GLP-1/glucagon triple agonistPhase 3Eli Lilly
CagrilintideLong-acting amylin analogPhase 3Novo Nordisk (paired with semaglutide as CagriSema)
SurvodutideGLP-1/glucagon dual agonistPhase 3Boehringer Ingelheim / Zealand Pharma
MazdutideGLP-1/glucagon dual agonistPhase 3 / approved in ChinaInnovent Biologics / Eli Lilly
OrforglipronOral non-peptide GLP-1 agonistPhase 3Eli Lilly
VK2735GIP/GLP-1 dual agonist (injectable and oral)Phase 2/3Viking Therapeutics
AmycretinGLP-1/amylin dual agonistPhase 2/3Novo Nordisk
PemvidutideGLP-1/glucagon dual agonistPhase 2Altimmune
Enicepatide (CT-388)GIP/GLP-1 dual agonistPhase 2Roche (via Carmot Therapeutics)
MariTide (maridebart cafraglutide)GIP/GLP-1 receptor bispecificPhase 3 (MARITIME program)Amgen
GSBR-1290 (aleniglipron)Oral non-peptide GLP-1 receptor agonistPhase 2bStructure Therapeutics
AZD5004 (elecoglipron)Oral non-peptide GLP-1 receptor agonistPhase 2 published, Phase 3 plannedAstraZeneca
RGT-075Oral non-peptide GLP-1 receptor agonistPhase 2bRegor Therapeutics
DanuglipronOral non-peptide GLP-1 receptor agonistDiscontinued (Apr. 2025, liver-injury signal)Pfizer

Early investigational

Earlier-phase candidates with limited public data so far.

CompoundMechanismStatusDeveloper
PetrelintideLong-acting amylin analogPhase 2Zealand Pharma
EloralintideAmylin analogPhase 2Eli Lilly
UBT251GIP/GLP-1/glucagon triple agonistEarly-to-mid phase (status disputed across sources)United Biotechnology
NisotirostideInvestigational incretin-class candidateEarly phaseNot yet disclosed
NBIP-1968Investigational incretin-class candidateEarly phaseNot yet disclosed
TERN-601Oral non-peptide GLP-1 receptor agonistPhase 2 (topline reported)Terns Pharmaceuticals
CT-996Oral non-peptide GLP-1 receptor agonistPhase 2, positive Phase 1Roche (via Carmot Therapeutics)
DapiglutideGLP-1/GLP-2 dual agonistPaused (positive Phase 1b, program paused for pipeline priorities)Zealand Pharma

This is a compilation of publicly available information for educational reference, not medical advice, and not a recommendation to use any of these compounds. Approval and trial status change frequently — check each compound’s own entry for the most current sourced detail. Page last reviewed September 2026.